๐ŸงฌTidera Health
โš•๏ธ

Educational tool only. Does not confirm eligibility or provide medical advice. Always consult your physician before pursuing any trial.

PulmonologyICD-10: J84.1

Find Recruiting Clinical Trials for Pulmonary Fibrosis

Search IPF, ILD, and progressive pulmonary fibrosis trials โ€” disease-modifying, antifibrotic, and transplant support studies.

๐Ÿ” Search Pulmonary Fibrosis Trials โ†’

About Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and ultimately fatal fibrotic lung disease with median survival of 3โ€“5 years from diagnosis. It is characterized by progressive scarring (fibrosis) of lung tissue, leading to worsening breathlessness and declining lung function. Two antifibrotic drugs โ€” nintedanib and pirfenidone โ€” slow disease progression but do not reverse fibrosis or halt disease. Progressive pulmonary fibrosis (PPF) describes fibrotic ILD in other diagnoses (hypersensitivity pneumonitis, connective tissue disease-associated ILD, unclassifiable ILD) that progresses despite treatment.

What Types of Pulmonary Fibrosis Clinical Trials Exist?

IPF/PPF clinical trials are among the most active in pulmonology. Programs include novel antifibrotic agents targeting different fibrotic pathways (LOXL2 inhibitors, CTGF inhibitors, PAR2 antagonists, TGF-ฮฒ pathway agents), combination antifibrotic strategies, add-on therapy to nintedanib or pirfenidone, inhaled antifibrotic delivery, and anti-inflammatory approaches for inflammatory-fibrotic overlap. FVC % predicted (forced vital capacity) is the primary eligibility and endpoint measure. Typical enrollment requires FVC 45โ€“90% predicted, confirmed UIP pattern on HRCT or biopsy.

Find Recruiting Pulmonary Fibrosis Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time โ€” matching trials to your age, location, and treatment history. Free, no account required.

Search Pulmonary Fibrosis Trials โ†’

Data from ClinicalTrials.gov ยท Updated in real time ยท Educational use only

Frequently Asked Questions

What clinical trials are available for pulmonary fibrosis?โ–พ
Recruiting IPF and PPF trials include novel antifibrotic agents, combination antifibrotic strategies (add-on to nintedanib or pirfenidone), inhaled antifibrotic delivery systems, anti-inflammatory/antifibrotic combination approaches, biomarker studies, and lung transplant support protocols. Given the limited efficacy of current therapies, IPF has one of the most active drug development pipelines in pulmonology.
What lung function do I need for IPF trials?โ–พ
Most IPF trials require FVC (forced vital capacity) between 45โ€“90% predicted โ€” confirming disease is present but not yet end-stage. DLCO (diffusing capacity) thresholds (typically โ‰ฅ25โ€“30% predicted) are also used. Both require pulmonary function testing (PFTs). A UIP pattern on HRCT chest CT and/or surgical lung biopsy is typically required to confirm the IPF diagnosis.
Can I join an IPF trial if I am already taking nintedanib or pirfenidone?โ–พ
Some IPF trials specifically test new agents as add-on therapy to background nintedanib or pirfenidone โ€” these allow and require continued standard antifibrotic therapy. Others test new monotherapy options and may require a washout period from current antifibrotics. Check the specific protocol, and never stop antifibrotic therapy without consulting your pulmonologist.

Related Conditions

COPDSystemic SclerosisLung Cancer

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.